Ernexa Therapeutics Inc. (ERNA)

Ernexa Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1.88	1.73	7.58	11.45	16.99
Cash & Short-Term Investments	1.88	1.73	7.58	11.45	16.99
Cash Growth	8.96%	-77.18%	-33.82%	-32.61%	942.02%
Other Receivables	0.85	0.44	0.43	0.95	0.68
Total Trade Receivables	0.85	0.44	0.43	0.95	0.68
Other Current Assets	0.4	0.19	1.6	1.28	1.1
Total Current Assets	3.13	2.35	9.6	13.68	18.77
Net Property, Plant & Equipment	0.55	0.76	33.27	1.27	3.24
Goodwill	2.04	2.04	2.04	2.04	2.04
Long-Term Investments	-	-	-	0.06	1
Other Long-Term Assets	0.11	0.12	4.22	5.23	6.48
Total Assets	5.83	5.27	49.13	22.28	31.53
Accounts Payable	1.13	1.72	1.07	1.62	1.76
Accrued Expenses	0.9	1.01	1.89	3.63	1.25
Current Portion of Leases	0.21	0.21	2.22	0.3	0.43
Unearned Revenue	-	-	0.19	-	-
Other Current Liabilities	0.88	0	1.31	2.11	0.25
Total Current Liabilities	3.11	2.94	6.57	7.65	3.68
Long-Term Debt	-	-	6.77	-	-
Long-Term Leases	0.28	0.48	32.85	0.89	2.3
Other Long-Term Liabilities	0.04	0.15	0.59	1.63	0.05
Total Long-Term Liabilities	0.32	0.63	40.22	2.52	2.35
Total Liabilities	3.43	3.57	46.9	10.17	6.02
Preferred Stock	0	0	0	0	0
Common Stock	0.04	0.02	0.03	0.03	0.01
Additional Paid-in Capital	248	233.22	189.19	177.38	166.19
Retained Earnings	-245.64	-231.54	-186.98	-165.3	-140.7
Shareholders' Equity	2.4	1.7	2.23	12.11	25.5
Total Liabilities & Equity	5.83	5.27	49.13	22.28	31.53
Total Debt	0.49	0.68	41.84	1.18	2.72
Net Cash (Debt)	1.39	1.05	-34.27	10.26	14.26
Net Cash Growth	33.40%	-	-	-28.03%	-
Net Cash Per Share	0.22	1.15	-96.80	50.46	98.81
Book Value	2.4	1.7	2.23	12.11	25.5
Book Value Per Share	0.38	1.87	6.31	59.52	176.70
Tangible Book Value	0.36	-0.34	0.19	10.06	23.46
Tangible Book Value Per Share	0.06	-0.38	0.53	49.47	162.53

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q